AACHEN, Germany, May 22, 2013 /CNW/ - Healthcare professionals who would
like to know more about the topical treatment of postherpetic neuralgia
(PHN) can now find useful information online. PHN is a chronic
disabling pain condition with symptoms often described as burning,
stabbing, or shooting pain, and caused by a previous herpes zoster
infection (commonly known as shingles). The new website answers
questions like "Why is PHN often misdiagnosed?" "Which questions help
making the correct diagnosis?" and "What are effective, well tolerated
and easy-to-use first-line treatment options?" Please visit http://www.versatis.com for details.
The Grünenthal Group is an independent, family-owned, international
research-based pharmaceutical company headquartered in Aachen, Germany.
Building on its unique position in pain treatment, its objective is to
become the most patient-centric company and thus to be a leader in
therapy innovation. Grünenthal is one of the last remaining five
research-oriented pharmaceutical companies with headquarters in Germany
which sustainably invests in research and development. The research and
development costs amounted to a preliminary of about 26 percent of
revenues in 2012. Grünenthal's research and development strategy
concentrates on selected fields of therapy and state-of-the-art
technologies. We are intensely focused on discovering new ways to treat
pain better and more effectively, with fewer side-effects than current
therapies. Altogether, the Grünenthal Group has affiliates in
26 countries worldwide. Grünenthal products are sold in more than
155 countries and today approx. 4,400 employees are working for the
Grünenthal Group worldwide. In 2012, Grünenthal achieved revenues of
€ 973 mn. More information: http://www.grunenthal.com.
Embargo: This information is intended for healthcare professionals only.
SOURCE: Grunenthal GmbH
For further information:
Jeanette Hübsch, Senior Manager Versatis, Grünenthal Europe & Australia
Phone: +49-241-569-1487, email: firstname.lastname@example.org